EP. 1: Exploring CAR T-Cell Therapy in Patients with Mantle Cell LymphomaAugust 2nd 2022
In an interview with Targeted OncologyTM, Leslie, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, discussed the CAR T-cell product, brexucabtagene autoleucel, and its influence on both MCL and indolent lymphomas.
Questioning Future Combinations and Targets for CAR T Cell in DLBCLFebruary 25th 2020
Lori A. Leslie, MD, discusses chimeric antigen receptor T-cell therapy as a treatment for diffuse large B-cell lymphoma and the positive results demonstrated for this agent in patients with relapsed/refractory disease.
Rationale for Treating Marginal Zone Lymphoma With PI3K-Delta Inhibitor UmbralisibJuly 9th 2019
Lori A. Leslie, MD, discusses the rationale for investigating the PI3K-delta inhibitor umbralisib in patients with relapsed or refractory marginal zone lymphoma in a multi-center, open-label phase II study. On trial, only patients with MZL were enrolled who had received at least 1 prior line of therapy. These patients received single-agent umbralisib once daily until progression or unacceptable toxicity.